Nationwide Fund Advisors boosted its stake in shares of Prothena Corp. (NASDAQ:PRTA) by 0.4% during the second quarter, Holdings Channel reports. The firm owned 51,659 shares of the company’s stock after buying an additional 219 shares during the period. Nationwide Fund Advisors owned about 0.15% of Prothena Corp. worth $1,806,000 as of its most recent filing with the SEC.
Other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP raised its position in Prothena Corp. by 29.0% in the first quarter. Wellington Management Group LLP now owns 3,216,685 shares of the company’s stock valued at $132,398,000 after buying an additional 722,889 shares during the period. BlackRock Institutional Trust Company N.A. raised its position in Prothena Corp. by 9.8% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 846,698 shares of the company’s stock valued at $34,850,000 after buying an additional 75,385 shares during the period. BlackRock Fund Advisors raised its position in Prothena Corp. by 10.0% in the first quarter. BlackRock Fund Advisors now owns 1,248,919 shares of the company’s stock valued at $51,406,000 after buying an additional 113,332 shares during the period. Bellevue Group AG purchased a new position in Prothena Corp. during the first quarter valued at $1,276,000. Finally, BlackRock Group LTD raised its position in Prothena Corp. by 23.1% in the first quarter. BlackRock Group LTD now owns 19,094 shares of the company’s stock valued at $785,000 after buying an additional 3,577 shares during the period.
Shares of Prothena Corp. (NASDAQ:PRTA) traded down 2.37% during midday trading on Friday, reaching $53.55. 406,402 shares of the company’s stock traded hands. Prothena Corp. has a 52 week low of $28.20 and a 52 week high of $76.42. The company’s market capitalization is $1.84 billion. The stock’s 50 day moving average is $57.27 and its 200-day moving average is $49.19.
Prothena Corp. (NASDAQ:PRTA) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($1.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by $0.27. The firm earned $0.33 million during the quarter, compared to analyst estimates of $0.39 million. Prothena Corp. had a negative net margin of 8,628.11% and a negative return on equity of 28.15%. Prothena Corp.’s quarterly revenue was up 22.2% compared to the same quarter last year. On average, analysts forecast that Prothena Corp. will post ($4.25) earnings per share for the current fiscal year.
PRTA has been the subject of several recent research reports. Credit Suisse Group AG reaffirmed a “buy” rating and set a $65.00 target price on shares of Prothena Corp. in a report on Sunday, September 11th. Zacks Investment Research lowered shares of Prothena Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, October 4th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Prothena Corp. in a report on Wednesday, June 22nd. Wedbush reaffirmed an “outperform” rating and set a $77.00 target price on shares of Prothena Corp. in a report on Monday, September 26th. Finally, Barclays PLC boosted their price target on shares of Prothena Corp. from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Prothena Corp. currently has an average rating of “Buy” and a consensus price target of $76.80.
In related news, insider Arthur W. Homan sold 3,125 shares of the stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $52.16, for a total transaction of $163,000.00. Following the completion of the sale, the insider now directly owns 3,125 shares of the company’s stock, valued at $163,000. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Karin L. Walker sold 12,000 shares of the stock in a transaction on Monday, September 19th. The stock was sold at an average price of $61.10, for a total value of $733,200.00. Following the sale, the insider now directly owns 7,000 shares of the company’s stock, valued at $427,700. The disclosure for this sale can be found here. 3.70% of the stock is owned by insiders.
Prothena Corp. Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Corp. (NASDAQ:PRTA).
Receive News & Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related companies with MarketBeat.com's FREE daily email newsletter.